Each year, almost 60,000 Americans are diagnosed with Parkinson’s disease (PD), but some of those patients might soon find relief for themselves and their families. Groundbreaking research at The Ohio State University Wexner Medical Center Neurological Institute suggests that transformational gene therapy could disrupt the circuits of neurodegenerative diseases, like Parkinson’s, to stop its progression through a one-time treatment that could halt the disease. Six clinical trials are currently in progress, and previous tests proved so effective that the Food and Drug Administration has helped to fast-track the registration of the therapy, which may be approved for treatment of patients this year.
For more information, visit medicine.osu.edu.